Myasthenia Gravis Therapeutics Pipeline
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong><br />
<strong>Pipeline</strong> to have Maximum Drugs to be<br />
Developed as Biologics<br />
enquiry@psmarketresearch.com<br />
www.psmarketresearch.com
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong><br />
According to a new research report “<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong> <strong>Pipeline</strong><br />
Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and<br />
Other Developments” published by P&S Market Research, <strong>Myasthenia</strong> <strong>Gravis</strong><br />
currently exhibits a pipeline of 19 drug candidates.<br />
Browse Detailed Summary at: https://www.psmarketresearch.com/marketanalysis/myasthenia-gravis-therapeutics-pipeline-analysis
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong><br />
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong> <strong>Pipeline</strong> in 2017<br />
The study analysed that the therapeutics pipeline comprises of approximately<br />
19 drug candidates in different stages of development. <strong>Myasthenia</strong> gravis is a<br />
chronic autoimmune disorder that acts on neuromuscular junction and leads to<br />
the weakening of skeletal muscles. This causes loss of muscle control in moving<br />
the body parts, such as the movement of arms and legs, breathing, loss of eye<br />
movements, chewing, talking, and swallowing. The situation of the disease<br />
worsens after a period of activity and improves after a period of rest.
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong><br />
Strategic Collaboration for the Development of<br />
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong><br />
Various companies, educational institutes and medical organizations are<br />
collaborating for the development of drugs for the treatment of this<br />
disease. For instance, Merck & Co., Inc. entered into a multi-targeted<br />
collaboration and license agreement with Ra Pharmaceuticals, Inc. to use<br />
the latter’s drug discovery technology platform for the development of<br />
orally available cyclic peptides for the treatment of myasthenia gravis.
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong><br />
Various Drug Candidates are Being Developed as<br />
Biologics<br />
It has been observed that most of the drugs in the myasthenia gravis<br />
therapeutics pipeline, are being developed from the natural source. NT-<br />
1654 is a heparan sulfate proteoglycan, and is under development by<br />
Neurotune AG for the treatment of myasthenia gravis. The drug acts as a<br />
neuromuscular junction stimulator.<br />
Some of the key players developing drugs for the treatment of myasthenia<br />
gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG<br />
and others.
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Therapeutics</strong><br />
Download report sample at:<br />
https://www.psmarketresearch.com/market-analysis/myastheniagravis-therapeutics-pipeline-analysis/report-sample
GET IN TOUCH<br />
THANK YOU!<br />
For information regarding permissions and other queries<br />
Kindly write to:<br />
enquiry@psmarketresearch.com<br />
US/Canada Toll-Free: 1-888-778-7886<br />
www.psmarketresearch.com
Change language